Actinium Pharmaceuticals
Führungskräfte
Siehe das Organigramm mit seine 20 wichtigsten Führungskräfte
Die meist gesuchten Biographien bei Actinium Pharmaceuticals
- Sandesh Seth, Chairman of the Board and Chief Executive Officer
- David Nicholson, Lead Independent Director
- Richard Steinhart, Director
Letzte Veränderungen der Führungskräfte auf Actinium Pharmaceuticals
- Lynn Bodarky, wurde beim Unternehmen als Chief Business Officer eingestellt (Nachrichten veröffentlicht am 3, November 2023).
Eine Benachrichtigung erstellen
um Veränderungen bei Führungskräften von Actinium Pharmaceuticals nachzuverfolgen.
Pharmazie
Actinium Pharmaceuticals hat 1.862 Konkurrenten , einschließlich Pfizer (USA), Sanofi (Frankreich) und Johnson & Johnson (USA).
Popular M&A news in Pharmazie
- MedMen has filed for bankruptcy protection (veröffentlicht am 28, April 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (veröffentlicht am 23, März 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (veröffentlicht am 19, März 2024).
Andere vorgeschlagene Kontakte der Pharmazie branche
Nachrichten
Neueste Pressemitteilungen nach Actinium Pharmaceuticals
- Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting :: Actinium Pharmaceu
- Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annua
- Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy :: Actinium Pharmaceuticals, Inc. (ATNM)
- Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMT
- Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIB
- Press Releases :: Actinium Pharmaceuticals, Inc. (ATNM)
- Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® :: Actinium Pharmaceuticals, Inc. (ATNM)
- Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia :: Actinium Pharmaceuticals, Inc. (ATNM)
- Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation :: Actinium Pharmaceuticals, Inc. (ATNM)
- Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition :: Actinium Pharmaceuticals, Inc. (ATNM)
- View more press releases Close
Social media about Actinium Pharmaceuticals
- Actinium Pharmaceuticals auf Wikipedia, Google News & Yahoo Finance
- Actinium Pharmaceuticals auf LinkedIn, Twitter & YouTube
In Kontakt kommen
Jetzt seine Führungskräfte, darunter auch Sandesh Seth, per E-Mail kontaktieren. 
Actinium Pharmaceuticals unter +1 646... anrufen
